The FDA and EMA have granted Orphan Drug Designation to zotiraciclib, currently the subject of two separate Phase Ib clinical trials in glioblastoma.
List view / Grid view
Filter the results
A new drug delivery technology has been developed using nanotubes which can efficiently and precisely target lung cancer cells.
A review of a study on children with liver cancer has shown the effectiveness of Transarterial Radioembolization with Yttrium-90 as a course of treatment...
Cardiac monitoring of high-risk breast cancer patients should be prioritised, after research revealed low rates of heart monitoring seen in the patients receiving trastuzumab.
Senescent, or zombie cells, are being targeted with the development of a new nanocarrier drug delivery system.
Once-daily oral pill could replace preoperative chemotherapy in patient population if validated in larger trials...
Protein inhibits inflammatory response underlying chronic pain processing may provide an alternative to opioids for severe, persistent pain...
With access challenges even after successful but costly development programmes, the industry is under pressure to speed up the clinical development process and produce more for less. Adaptive trial designs, more collaborative working and data sharing could provide a solution in the area of cancer immunotherapy, says Jacqueline Karmel, principal…
New research suggests that treatment with a shorter course of radiation using higher doses over fewer days may be the preferred approach for some men with intermediate-risk prostate cancer.
A new report shows that the UK is trailing behind the rest of Europe in the diagnosis and treatment of cancer.
The FDA has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with metastatic non-small cell lung cancer.